Sale!

Extended AML Panel BCRABLAMLETO CBFB PMLRARA FLT3 NPM1 CEBPA Test Cost

Original price was: 7,200 د.إ.Current price is: 5,400 د.إ.

-25%

The Extended AML (Acute Myeloid Leukemia) Panel is a comprehensive diagnostic test designed to detect specific genetic mutations and translocations associated with AML. This panel targets several key genes, including BCR-ABL, AML1-ETO (also known as RUNX1-RUNX1T1), CBFB, PML-RARA, FLT3, NPM1, and CEBPA. These genetic markers are crucial for diagnosing AML, determining prognosis, and guiding treatment decisions. The presence or absence of these mutations can significantly influence a patient’s response to certain therapies, making this panel an essential tool in personalized medicine for AML patients.

Performed at DNA Labs UAE, a leading facility in genetic testing, the Extended AML Panel is executed with precision and accuracy, ensuring reliable results for patients and healthcare providers. The cost of the test is 5400 AED, reflecting the comprehensive nature of the analysis and the advanced technology employed in the process. By identifying specific genetic abnormalities, this test can help in tailoring treatment plans to the individual’s genetic profile, potentially improving outcomes in AML treatment.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Extended AML Panel BCRABLAMLETO CBFB PMLRARA FLT3 NPM1 CEBPA Test

Price: 5400.0 AED

Sample Condition: Bone marrow / Peripheral blood (Transport immediately)

Report Delivery: 7-8 days

Method: Sanger Sequencing

Test Type: Genetics

Doctor: Gynecologist

Test Department: Pre Test Information

Extended AML Panel (BCR/ABL, AML/ETO, CBFB, PML/RARA, FLT3, NPM1, CEBPA) can be done with a doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

The Extended AML Panel is a set of genetic tests that are used to diagnose and monitor patients with acute myeloid leukemia (AML). This panel includes tests for mutations in the following genes:

  1. BCR/ABL: This gene is associated with chronic myeloid leukemia (CML), but can also be present in a small percentage of AML cases.
  2. AML/ETO: This gene fusion is found in about 20% of AML cases and is associated with a poorer prognosis.
  3. CBFB: Mutations in this gene are found in about 15% of AML cases and are associated with a better prognosis.
  4. PML/RARA: This gene fusion is found in about 5-10% of AML cases and is associated with acute promyelocytic leukemia (APL).
  5. FLT3: Mutations in this gene are found in about 30% of AML cases and are associated with a poorer prognosis.
  6. NPM1: Mutations in this gene are found in about 30% of AML cases and are associated with a better prognosis.
  7. CEBPA: Mutations in this gene are found in about 10% of AML cases and are associated with a better prognosis.

By analyzing these genes, doctors can determine the specific subtype of AML a patient has, which can help guide treatment decisions. Additionally, monitoring changes in these genes over time can help doctors assess a patient’s response to treatment and detect any potential relapse.

Test Name Extended AML Panel BCRABLAMLETO CBFB PMLRARA FLT3 NPM1 CEBPA Test
Components EDTA Vacutainer (2ml)
Price 5400.0 AED
Sample Condition Bone marrow \/ Peripheral blood (Transport immediately)
Report Delivery 7-8 days
Method Sanger Sequencing
Test type Genetics
Doctor Gynecologist
Test Department:
Pre Test Information Extended AML Panel (BCR/ABL,AML/ETO, CBFB, PML/RARA, FLT3, NPM1, CEBPA) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

The Extended AML Panel is a set of genetic tests that are used to diagnose and monitor patients with acute myeloid leukemia (AML). This panel includes tests for mutations in the following genes:

1. BCR/ABL: This gene is associated with chronic myeloid leukemia (CML), but can also be present in a small percentage of AML cases.

2. AML/ETO: This gene fusion is found in about 20% of AML cases and is associated with a poorer prognosis.

3. CBFB: Mutations in this gene are found in about 15% of AML cases and are associated with a better prognosis.

4. PML/RARA: This gene fusion is found in about 5-10% of AML cases and is associated with acute promyelocytic leukemia (APL).

5. FLT3: Mutations in this gene are found in about 30% of AML cases and are associated with a poorer prognosis.

6. NPM1: Mutations in this gene are found in about 30% of AML cases and are associated with a better prognosis.

7. CEBPA: Mutations in this gene are found in about 10% of AML cases and are associated with a better prognosis.

By analyzing these genes, doctors can determine the specific subtype of AML a patient has, which can help guide treatment decisions. Additionally, monitoring changes in these genes over time can help doctors assess a patient’s response to treatment and detect any potential relapse.